SRP-9001

FDA questions benefits, risks of Sarepta DMD gene therapy

An FDA committee will consider whether evidence supports the benefits and risks of Sarepta's DMD gene therapy on Friday. The agency seems unconvinced.

Annalee Armstrong May 10, 2023 11:02am

Roche delays DMD drug, amends MS trials in face of Ukraine war

Apr 25, 2022 11:41am